Drugs for bone healing

Expert Opinion on Investigational Drugs

Volumn 21, Issue 8, 2012, Pages 1169-1176

  Brandi, Maria Luisa ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

anabolics; anti sclerostin antibody; antiresorptives; bone formation; bone healing; bone morphogenetic proteins; growth factors; parathyroid hormone peptides; strontium ranelate

Indexed keywords

ALENDRONIC ACID; BAZEDOXIFENE; CALCITONIN; DENOSUMAB; DICKKOPF 1 PROTEIN; ESTROGEN; IBANDRONIC ACID; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RISEDRONIC ACID; RONACALERET; SCLEROSTIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM; STRONTIUM RANELATE; ZOLEDRONIC ACID;

ADJUVANT THERAPY; AVASCULAR NECROSIS; BONE CELL; BONE DEFECT; BONE REGENERATION; BONE REMODELING; CALLUS; CANCER PATIENT; CELL REGENERATION; CLINICAL EVALUATION; DOUBLE BLIND PROCEDURE; FRACTURE HEALING; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; IN VIVO STUDY; NEOPLASM; NONHUMAN; ORTHOPEDIC SURGEON; OSTEOBLAST; OSTEOLYSIS; OSTEOPOROSIS; OSTEOSYNTHESIS; OSTEOTOMY; PHASE 2 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE; QUALITY OF LIFE; RADIUS FRACTURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TIBIA FRACTURE; VASCULARIZATION;

BONE AND BONES; BONE REGENERATION; CLINICAL TRIALS, PHASE II AS TOPIC; FRACTURE HEALING; FRACTURES, BONE; HUMANS;

EID: 84863682529     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2012.696610     Document Type: Review

References (77)

1. MacKenzie EJ, Bosse MJ, Pollak AN, et al. Long-term persistence of disability following severe lower-limb trauma. Results of a seven-year follow-up. J Bone Joint Surg Am 2005;87:1801-9 (Pubitemid 41061201)
2. Parfitt AM. Osteonal and hemi-osteonal remodelling: the spatial and temporal framework for signal traffic in adult human bone. J Cell Biochem 1994;55:273-86 The manuscript provides the cellular basis of the bone repair program. (Pubitemid 24218802)
3. Al-Aql ZS, Alagl AS, Graves DT, et al. Molecular mechanisms controlling bone formation during fracture healing and distraction osteogenesis. J Dent Res 2008;87:107-18
4. Ferguson C, Alpern E, Miclau T, Hels JA. Does adult fracture repair recapitulate embryonic skeletal formation? Mech Dev 1999;87:57-66 (Pubitemid 29428086)
5. Gerstenfeld LC, Cullinane DM, Barnes GL, et al. Fracture healing as a post-natal developmental process: molecular, spatial, and temporal aspects of ist regulation. J Cell Biochem 2003;88:873-84 The manuscript covers the basic molecular mechanisms of the bone healing process. (Pubitemid 36337032)
6. Gerstenfeld LC, Alkhiary YM, Krall EA, et al. Three-dimensional reconstruction of fracture callus morphogenesis. J Histochem Cytochem 2006;54:1215-28 (Pubitemid 44623342)
7. Dimitriou R, Tsiridis E, Giannoudis PV. Current concepts of molecular aspects of bone healing. Injury 2005;36:1392-404 The manuscript masters the full cellular and molecular mechanisms of bone repair. (Pubitemid 41618169)
8. Food and Drug Administration: Medical Devices. Available from: http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ DeviceApprovalsandClearances/Recently-ApprovedDevices/default.htm
9. Nauth A, Giannoudis PV, Einhorn TA, et al. Growth factors: beyond bone morphogenetic proteins. J Orthop Trauma 2010;24:543-6
10. Simpson AH, Mlls L, Noble B. The role of growth factors and related agents in accelerating fracture healing. J Bone Joint Surg Br 2006;88:701-5 (Pubitemid 43971130)
11. Blokhuis TJ. Formulations and delivery vehicles for bone morphogenetic proteins: latest advances and future directions. Injury 2009;40:S8-11
12. Dimitriou R, Jones E, McGonagle D, Giannoudis PV. Bone regeneration current concepts and future directions. BMC Med 2011;9:66-76 The manuscript offers a full spectrum of information for the bone repair cascade.
13. Alsousou J, Thompson M, Hulley P, et al. The biology of platelet-rich plasma and its application in trauma and orthopaedic surgery: a review of the literature. J Bone Joint Surg Br 2009;91:987-96
14. Vavken P, Sadoghi P, Murray MM. The effect of platelet concentrates on graft maturation and graft-bone interface healing in anterior cruciate ligament reconstruction in human patients: a systematic review of controlled trials. J Arthrosc Rel Surg 2011;27:1573-83
15. Agintar E, Edwards S, Delahay J. Bone morphogenetic proteins in orthopaedic trauma surgery. Injury 2010;42(8):730-4
16. Chen FM, Ma ZW, Dong GY, Wu ZF. Composite glycidyl methacrylated dextran (DexGMA)/gelatin nanoparticles for localized protein delivery. Acta Pharmacol Sin 2009;30:485-93
17. Giannoudis PV, Einhorn TA, Marsh D. Fracture healing: the diamond concept. Injury 2007;3854:53-6 The manuscript describes the diamond concept so important in the bone repair control with exogenous agents.
18. Hernigou PH, Poignard A, Beaujean E, Rouard H. Percutaneous autologous bone-marrow grafting for nonunions. J Bone Joint Surg 2005;87A:1430-7
19. Charbord P, Livne E, Gross G, et al. Human bone marrow mesenchymal stem cells: a systematic reappraisal via the genostem experience. Stem Cell Rev Rep 2011;7:32-42
20. Aspenberg P. Drugs and fracture repair. Acta Orthop 2005;76-6:741-8 The manuscript reviews the pharmacological interventions in bone healing.
21. Einhorn TA. Enhancement of fracture-healing. J Bone Joint Surg Am 1995;77:6:940-56
22. Jorgensen NR, Schwarz P. Effects of anti-osteoporosis medications on fracture healing. Curr Osteoporos Rep 2011;9:149-55
23. Bukata SV. Systemic administration of pharmacological agents and bone repair: what can we expect. Injury 2011;42:605-8
24. Goldhahn J, Mitlak BH, Asperberg P, et al. Critical issues in translational and clinical research for the study of new technologies to enhance bone repair. J Bone Joint Surg Am 2008;90:40-3
25. Goldhahn J, Scheele WH, Mitlak BH, et al. Clinical evaluation of medicinal products for acceleration of fracture healing in patients with osteoporosis. Bone 2008;43:343-7 The manuscript poses the basis for the definition of the parameters that will define a drug as bone "healer".
26. Goldhahn J, Little D, Mitchell P, et al. Evidence for anti-osteoporosis therapy in acute fracture situations-recommendations of a multidisciplinary workshop of the International Society for Fracture Repair. Bone 2010;46:267-71
27. Ferguson C, Alpern E, Miclau T, Helms JA. Does adult fracture repair recapitulate embryonic skeletal formation? Mech Dev 1999;87:57-66 (Pubitemid 29428086)
28. Einhorn TA. The cell and molecular biology of fracture healing. Clin Orthop Relat Res 1998;355:S7-21
29. Adams GB, Martin RP, Alley IR, et al. Therapeutic targeting of a stem cell niche. Nature Biotechnol 2007;25:238-43 (Pubitemid 46227124)
30. Butcher JL, MacKenzie EJ, Cushing B, et al. Long-term outcomes after low extremity trauma. J Trauma 1996;41:4-9 (Pubitemid 26250864)
31. MacKenzie EJ, Bosse MJ, Pollak AN, et al. Long-term persistence of disability following severe lower-limb trauma. Results of a seven-year follow-up. J Bone Joint Surg Am 2005;87:1801-9 (Pubitemid 41061201)
32. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-22 (Pubitemid 46698462)
33. Craig SJ, Youssef PP, Vaile JH, et al. Intravenous zoledronate and oral alendronate in patients with a low trauma fracture- experience from an osteoporosis clinic. Intern Med J 2010;41:186-90
34. Cao Y, Mori S, Mashiba T, et al. Raloxifene, estrogen, and alendronate affect the processes of fracture repair differently in ovariectomized rats. J Bone Miner Res 2002;17:2237-46 (Pubitemid 35416758)
35. Langeland N. Effects of oestradiol-17 beta benzoate treatment on fracture healing and bone collagen synthesis in female rats. Acta Endocrinol (Copenh) 1975;80:603-12
36. Meyer RA Jr, Tsahakis PJ, Martin DF, et al. Age and ovariectomy impair both the normalization of mechanical properties and the accretion of mineral by the fracture callus in rats. J Orthop Res 2001;19:428-35 (Pubitemid 32472013)
37. Yingjie H, Ge Z, Yisheng W, et al. Changes of microstructure and mineralized tissue in the middle and late phase of osteoporotic fracture healing in rats. Bone 2007;41:631-8 (Pubitemid 47385430)
38. Bannister GC, Gibson AG, Ackroyd CE, et al. The fixation and prognosis of trochanteric fractures. A randomized prospective controlled trial. Clin Orthop Relat Res 1990;254:242-6 (Pubitemid 20145911)
39. Sadowski C, Lubbeke A, Saudan M, et al. Treatment of reverse oblique and transverse intertrochanteric fractures with use of an intramedullary nail or a 95 degrees screwplate: a prospective, randomized study. J Bone Joint Surg Am 2002;84-A:372-81 (Pubitemid 37107707)
40. Schmidmaier G, Lucke M, Schwabe P, et al. Collective review: bioactive implants coated with poly(D, L-lactide) and growth factors IGF-I, TGF-beta1, or BMP-2 for stimulation of fracture healing. J Long Term Eff Med Implants 2006;16:61-9
41. Kais MS, Einhorn TA. Recombinant human bone morphogenetic proteins in the treatment of fractures. Foot Ankle Clin 2005;10:639-50; viii
42. Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010;25:2267-94 The manuscript describes the problem of atypical fractures in aminobisphosphonate treated patients.
43. Goodship AE, Walker PC, McNally D, et al. Use of a bisphosphonate (pamidronate) to modulate fracture repair in ovine bone. Ann Oncol 1994;5(Suppl 7):S53-5
44. Nauth A, Miclau T, Bhandari M, Schemitsch EH. Use of osteobiologics in the management of osteoporotic fractures. J Orthop Trauma 2011;25:S51-5
45. Kinov P, Tivchev P, Doukova P, Leithner A. Effect of risedronate on bone metabolism after total hip arthroplasty: a prospective randomized study. Arch Orthop Belg 2006;72:44-50
46. Hilding M, Aspenberg P. Local preoperative treatment with bisphosphonate improves the fixation of total knee prostheses. Acta Orthoped 2007;78:795-9
47. Solomon HMC, Mogun H, Schneeweiss S. The relation between bisphosphonate use and non-union of fractures of the humerus in older adults. Osteoporos Intv 2009;20:895-201
48. Moroni A, Faldini C, Hoang-Kim A, et al. Alendronate improves screw fixation in osteoporotic bone. J Bone Joint Surg Am 2007;89:96-101 (Pubitemid 46059148)
49. Rozental TD, Vazquez MA, Chacko AT, et al. Comparison of radiographic fracture healing in the distal radius for patients on and off bisphosphonate therapy. J Hand Surg Am 2009;34:595-602
50. Colon-Emeric C, Nordsletten L, Olson S, et al. Association between timing of zoledronic acid infusion and hip fracture healing. Osteoporos Int 2010;22(8):2329-36
51. Gerstenfeld LC, Sacks DJ, Pelis M, et al. Comparison of effects of the bisphosphonate alendronate versus the RANKL inhibitor denosumab on murine fracture healing. J Bone Miner Res 2009;24:196-208
52. Stuermer EK, Sehmisch S, Rack T, et al. Estrogen and raloxifene improve metaphyseal fracture healing in the early phase of osteoporosis. A new fracture-healing model at the tibia in the rat. Langenbecks Arch Surg 2010;395:163-72
53. Neer RM, Arnaud CD, Zancgetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41 (Pubitemid 32402100)
54. Greenspan SL, Bone HG, Ettinger MP, et al. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med 2007;146:326-39 (Pubitemid 351650593)
55. Ellegaard M, Jorgensen NR, Scwarz P. Parathyroid hormone and bone healing. Calcif Tissue Int 2010;87:1-13
56. Aspenberg P, Genant HK, Johansson T, et al. Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res 2010;25:404-14 The manuscript describes the first controlled clinical trial on the use of an antifracture agent in the induction of fracture repair.
57. Aspenberg P, Johansson T. Teriparatide improves early callus formation in distal radius fractures. Analysis of a subgroup of patients within a randomized trial. Acta Orthopaed 2010;81:234-6
58. Resmini G, Iolascon G. 79-year-old post-menopausal woman with humerus fracture during teriparatide treatment. Aging Clin Exp Res 2007;19(4 Suppl):30-1
59. Hodsman AB, Hanley DA, Ettinger MP, et al. Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab 2003;88:5212-20 (Pubitemid 37452718)
60. Whitfield JF, Morley P, Willick G, et al. Cyclization by a specific lactam increases the ability of human parathyroid hormone (hPTH)-(1-31)NH2 to stimulate bone growth in ovariectomized rats. J Bone Miner Res 1997;12:1246-52 (Pubitemid 27334971)
61. Peichl P, Holzer LA, Maier R, Olzer G. Parathyroid hormone 1-84 accelerates fracture-healing in pubic bones of elderly osteoporotic women. J Bone Joint Surg 2011;93:1583-7
62. Li YF, Zhou CC, Li JH, et al. The effects of combined human parathyroid hormone (1-34) and zoledronic acid treatment on fracture healing in osteoporotic rats. Osteoporos Int 2011. [Epub ahead of print]
63. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350:459-68 (Pubitemid 38133766)
64. Maimoun L, Brennan TC, Badoud I, et al. Strontium ranelate improves implant osseointegration. Bone 2010;46:1436-41
65. Li Y, Feng G, Gao Y, et al. Strontium ranelate treatment enhances hydroxyapatite-coated titanium screws fixation in osteoporotic rats. J Orthop Res 2010;28:578-82
66. Cebesoy O, Tutar E, Kose KC, et al. Effect of strontium ranelate on fracture healing in rat tibia. Joint Bone Spine 2007;74:590-3 (Pubitemid 350236018)
67. Li YF, Luo E, Zhu SS, et al. Systemic treatment with strontium ranelate promotes tibial fracture healing in ovariectomized rats. Osteoporos Int 2010;21:1889-97 The manuscript describes the effect of an anabolic agent, strontium ranelate, on the bone healing process in an animal model.
68. Bruel A, Olsen J, Birkedal H, et al. Strontium is incorporated into the fracture callus but does not influence the mechanical strength of healing rat fractures. Calcif Tissue Int 2011;88:142-52
69. Habermann B, Kafchitsas K, Olender G, et al. Strontium ranelate enhances callus strength more than PTH 1-34 in an osteoporotic rat model of fracture healing. Calcif Tissue Int 2010;86:82-9
70. Alegre DN, Ribeiro C, Sousa C, et al. Possible benefits of strontium ranelate in complicated long bone fractures. Rheumatol Int 2012;32:439-43
71. Tarantino U, Celi M, Saturnino L, et al. Strontium ranelate and bone healing: report of two cases. Clin Cases Miner Bone Metab 2010;7:65-8
72. Komatsu DE, Mary MN, Schroeder RJ, et al. Modulation of Wnt signaling influences fracture repair. J Orthop Res 2010;28:928-36
73. Ominsky MS, Li C, Li X, et al. Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones. J Bone Miner Res 2011;26:1012-21
74. Kumar S, Matheny CJ, Hoffman SJ, et al. An orally active calcium-sensing receptor antagonist that transiently increases plasma concentrations of PTH and stimulates bone formation. Bone 2010;46:534-42
75. Fitzpatrick LA, Brennan E, Kumar S, et al. Ronacaleret, a novel calcium-sensing receptor antagonist, demonstrates potential as an oral bone-forming therapy in healthy postmenopausal women. J Bone Miner Res 2008;23:S50
76. Bone Fitzpatrick LA, Smith PL, McBride TA, et al. Ronacarelet, a calcium-sensing receptor antagonist, has no significant effect on radial fracture healing time: results of a randomized, double-blinded, placebo-controlled Phase II clinical trial. Bone 2011;49:845-52
77. Takahata M, Schwarz EM, Chen T, et al. Delayed short course treatment with teriparatide (PTH(1-34)) improves femoral allograft healing by enhancing intramembranous bone formation at the graft-host junction. J Bone Miner Res 2011;27:26-37